Extended Imatinib Maintenance Boosts Disease-Free Survival in High-Risk GIST

(MedPage Today) -- Patients with high-risk gastrointestinal stromal tumors (GISTs) had a 60% improvement in 3-year disease-free survival (DFS) with 6 versus 3 years of maintenance imatinib, a randomized trial showed.
DFS at 3 years increased from...